TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Smaller drop in SpO2 during acute hypoxic test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional liver regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean daily blood glucose (BG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: prevalence of hypoglycemia (<70 mg/dL)
Endpoint domain: Adverse events/effects
Primary endpoint: FOBT completion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco dependence as measured by the WISDM total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence rates of new macular hemorrhages
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in neck disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in range of rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Analgesic efficacy (pain intensity difference)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular death or congestive heart failure at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Mean score of MFA
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: treatment failure in correcting IDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: treatment failure in correcting ID
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: treatment failure in correcting anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Erythrocyte MDA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival correlated with baseline Nt-pro-ANP and reduction in BNP
Endpoint domain: Mortality/survival
Primary endpoint: anginal threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ability to discriminate individual voices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset time for sensory and motor blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time for sensory and motor blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin resistance values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of screen-detected lung cancers that are early stage
Endpoint domain: Mortality/survival
Primary endpoint: Willingness to enroll in a disease management program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS drug liking
Endpoint domain: Adverse events/effects
Primary endpoint: Overall opinion on the POSAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hyper- or hypoesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of major adverse cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage variation of MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative amount excreted unchanged (X(u))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Excretion rate (K(e))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Elimination constant (K(el))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anxiety proneness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Monotony Avoidance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: OSBD-R scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery times
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 12-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Proliferation fraction (PF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S-phase fraction (SPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration of muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum 25OHD concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participants achieving serum 25OHD concentrations ≥20 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial nerve function recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-aurem pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective rate of treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mindfulness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Length of Stay (LOS) for nonurgent patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Stay (LOS) for urgent patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MR severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Genotype indicative of high IL-10 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effect of treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in pad weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inter-observer disagreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-observer disagreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Hb levels above 13 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CBT-retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: crack-cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin-stimulated peripheral glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Limb fat change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incident STD
Endpoint domain: Adverse events/effects
Primary endpoint: Reported sexual risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Incidence of severe OHSS
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy rate (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ileal fluorescein leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Microerosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dry Eye Symptom Score (DESS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flare-up of Lacrimal Clearance Score (FLCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced oxidative stress and pro-inflammatory levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower serum cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved mood scores (POMS evaluation)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BMD Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crying frequency during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crying duration during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal IOP during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: IOP >21 mm Hg and/or application of topical antiglaucomatous medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Serum HCV-RNA titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLCO (Diffusing capacity of the lungs for carbon monoxide)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: serum PSA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karnofsky score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FACT-P score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: seroprotection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: antihepatitis A virus geometric mean titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall CPR compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of IL-11 in portal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of unwanted effects
Endpoint domain: Adverse events/effects
Primary endpoint: Pruritus incidence
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in psychopathology scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque removal percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to opening eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to be fit for discharge from the recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fERG amplitude change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual acuity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tear stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ocular surface status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2 transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: carbon dioxide transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pressure drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Deficit in one or more tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 1.25‐(OH)2 D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: total calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of acute otitis media (OM) in implanted ear
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed PMN apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PMN priming for superoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of residual CBD stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to continue use scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Critical errors made
Endpoint domain: Adverse events/effects
Primary endpoint: spontaneous DNA strand breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-stage renal disease (ESRD) rate
Endpoint domain: Mortality/survival
Primary endpoint: frequency of radiolucent lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diabetes self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-reported adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in estimated percentage breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of PGE2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reversal of fetal ductal constriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduction in SeSBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in SeDBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achievement of BP goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: regional CBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: tolerance threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic cytokine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Surgical deaths
Endpoint domain: Mortality/survival
Primary endpoint: Protection against methacholine induced bronchoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rescue salbutamol use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nasal dryness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal crusting improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social anxiety measures improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual Intercourse (SI) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IIEF-5 score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: motor block duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite z score including resting BP, LDL-C, fasting glucose, and percent body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of new or enlarging T2-hyperintense lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: number of new nonenhancing T1-hypointense lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: total lesion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mean subjective sleep latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Maturation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: H. pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Material failure of spinal implants
Endpoint domain: Adverse events/effects
Primary endpoint: efficacy of phototherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of severe SRs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients achieving the target maintenance dose (TMD)
Endpoint domain: Physiological/clinical
Primary endpoint: Length of time to attain the TMD
Endpoint domain: Physiological/clinical
Primary endpoint: At least one TEAE reported
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Memory for emotional pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pullback gradient across the conduit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in right ventricular/aortic pressure ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in New York Heart Association functional class I
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Increase in handwashing with soap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parental expectancy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Favourable changes in psychopathological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of spontaneous interferon γ production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flank recurrence
Endpoint domain: Mortality/survival
Primary endpoint: good outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Low energy or fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Poor concentration or indecisiveness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction of tissue factor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in formation of tumor necrosis factor-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in formation of thromboxane B2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: allogeneic erythrocyte requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: myocardial infarctions (MI)
Endpoint domain: Mortality/survival
Primary endpoint: cardiac death plus MI
Endpoint domain: Mortality/survival
Primary endpoint: Absolute bioavailability of rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-infinity) for ranitidine + IV rosiglitazone vs IV rosiglitazone alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-infinity) for ranitidine + oral rosiglitazone vs oral rosiglitazone alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle function score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination half-life of Ringer's acetate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of impaired glucose tolerance (IGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of impaired fasting glucose (IFG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in craving ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporary tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Helpfulness to stop smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement rate in detecting reversible defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: surgical cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: tracheotomy rate
Endpoint domain: Adverse events/effects
Primary endpoint: Deglutition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aesthetic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall of medicine name
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct use of medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in arm strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: duration of sensory loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h urinary protein excretion (U‐Pro)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum albumin (ALB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity and duration of Pityriasis rosea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Executive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque and gingival scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sensitivity to interference subtest of the FAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in anxiety level (HADS-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in MMSE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall arterial contrast density (CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes